<DOC>
	<DOCNO>NCT00453206</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine , busulfan , melphalan , donor peripheral stem cell transplant bone marrow transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving tacrolimus , methotrexate , mycophenolate mofetil , antithymocyte globulin transplant may stop happen . Once donated stem cell begin work , patient 's immune system may see remain cancer abnormal cell belong patient 's body destroy ( graft-versus-tumor effect ) . Giving infusion donor 's white blood cell ( donor lymphocyte infusion ) may boost effect . PURPOSE : This phase II trial study well donor stem cell transplant work treat patient hematologic cancer disease .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Hematologic Cancer Other Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility ( i.e. , risk treatment-related mortality first 6 month transplantation ) administer reduced-intensity allogeneic hematopoietic stem cell transplantation patient hematologic cancer disease . Secondary - Determine response rate ( partial complete response ) , 6- 12-month probability response , time progression patient treat regimen . - Determine risk acute chronic graft-versus-host disease patient treat regimen . - Determine toxicity regimen patient . - Determine overall survival disease-free survival patient treat regimen . - Determine impact iron status overall disease-free survival . - Determine influence quality life ( time transplantation ) overall survival . OUTLINE : - Preparative regimen : Patients receive fludarabine phosphate IV 30 minute day -7 -3 . Patients also receive busulfan IV 2 hour every 6 hour day -4 -3 melphalan IV 2 hour day -3 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients match related donor receive oral tacrolimus twice daily day -1 90 followed taper day 180 . Patients also receive methotrexate IV day 1 , 3 , 6 . Patients match unrelated 9/10 match related donor receive oral tacrolimus twice daily day -1 180 follow taper ; methotrexate IV day 1 , 3 , 6 , 11 ; oral mycophenolate mofetil twice daily day -2 60 follow taper . All patient also receive antithymocyte globulin IV 4 6 hour day day -4 -1 . - Allogeneic stem cell transplantation : Patients undergo allogeneic peripheral blood stem cell transplantation bone marrow transplantation day 0 . Patients receive filgrastim ( G-CSF ) begin day 7 continue blood count recover . - Lymphocyte infusion : Patients progressive stable disease immunosuppression active GVHD may receive 3 donor lymphocyte infusion original donor 8-week interval begin day 180 210 . Quality life assess baseline . After completion study therapy , patient follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>Histologically confirm hematological disease , include follow : Chronic lymphocytic leukemia Absolute lymphocytosis &gt; 5,000/µL Morphologically mature lymphocytes &lt; 55 % prolymphocytes Lymphocyte phenotype expression CD19 CD5 Absence CD23 expression allow provided disease morphologically distinguish mantle cell lymphoma Prolymphocytic leukemia Absolute lymphocytosis &gt; 5,000/µL Morphologically mature lymphocytes &gt; 55 % prolymphocytes NonHodgkin 's Hodgkin 's lymphoma Any WHO classification histologic subtype Diagnosis core biopsy allow provided adequate tissue diagnosis immunophenotyping Diagnosis bone marrow biopsy acceptable follicular lymphoma Multiple myeloma Has receive ≥ 1 prior treatment regimen Has partial response great Blade Criteria Patients achieve complete remission eligible Acute myeloid leukemia Documented control ( i.e. , &lt; 10 % bone marrow blast circulate blast ) Myelodysplastic syndromes Documented disease define WHO FrenchAmericanBritish Cooperative group criterion Chronic myelogenous leukemia Patients atypical chronic myelogenous leukemia ( i.e. , absent Philadelphia chromosome ) eligible Polycythemia vera Documented disease define WHO criteria ( i.e. , A1 + A2 , category A , OR A1 + A2 , 2 category B ) : A1 : Total red blood cell mass &gt; 25 % mean normal predict value OR hemoglobin &gt; 18.5 g/dL male , 16.5 g/dL female ( hematocrit ≥ 60 % male ≥ 56 % female ) A2 : No cause secondary erythrocytosis ( absence familial erythrocytosis , elevation epoetin alfa [ EPO ] due hypoxia , high oxygen affinity hemoglobin , truncate EPO receptor , inappropriate ectopic EPO production ) A3 : Splenomegaly A4 : Clonal genetic abnormality Philadelphia chromosome A5 : Endogenous erythroid colony formation vitro B : Platelet count &gt; 400,000/mm³ , WBC &gt; 12,000/mm³ , bone marrow biopsy prominent erythroid megakaryocytic proliferation , low serum EPO Chronic idiopathic myelofibrosis Documented disease define WHO criteria Must HLAidentical donor , match unrelated donor , HLA 9/10 relate donor meeting follow criterion : HLAidentical sibling ( 6/6 ) Serologic type class I ( A , B ) Molecular type class II ( DRB1 ) 9/10 match relate donor Highresolution molecular type HLAA , B , C , DRB1 , DQB1 Only single mismatch one class I II allele allow 10/10 matched unrelated donor Molecular identity HLAA , B , C , DRB1 , DQB1 highresolution type Syngeneic donor eligible Creatinine clearance ≥ 40 mL/min Bilirubin ≤ 3 time upper limit normal ( ULN ) AST ≤ 3 time ULN DLCO ≥ 40 % symptomatic pulmonary disease LVEF ≥ 30 % cardiac MRI echocardiogram symptomatic cardiac disease Fertile patient willing use effective contraception Uncontrolled diabetes mellitus Active serious infection Known hypersensitivity E. coliderived product Known HIV positivity History another malignancy* , meet follow criterion : Nonskin malignancy melanoma within past 5 year Concomitant malignancy curatively treated NOTE : *However , cancer survivor undergo potentially curative therapy prior malignancy least 5 year enrollment deem low risk &lt; 30 % recurrence treat physician consider Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage I childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage II childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage III childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
</DOC>